Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
93 hedge funds and large institutions have $122M invested in Eiger BioPharmaceuticals, Inc. in 2020 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 41 increasing their positions, 20 reducing their positions, and 16 closing their positions.
105% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 20
19% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 16
2% more funds holding
Funds holding: 91 → 93 (+2)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
56% less capital invested
Capital invested by funds: $275M → $122M (-$153M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $78K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$19M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$4.44M |
| 3 |
JGC
J. Goldman & Co
New York
|
+$3.98M |
| 4 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
+$2.29M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$2.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$21.6M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$11.1M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$6.7M |
| 4 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$3.04M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$1.74M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCP
101
GSA Capital Partners
London,
United Kingdom
| – | -$192K | -431 | Closed |
|
|
MIM
102
MetLife Investment Management
Whippany,
New Jersey
| – | -$188K | -421 | Closed |
|
|
LI
103
Leap Investments
Chicago,
Illinois
| – | -$159K | -357 | Closed |
|
|
PVH
104
Psagot Value Holdings
Tel Aviv,
Israel
| – | -$137K | -307 | Closed |
|
|
MLICM
105
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$120K | -269 | Closed |
|
|
WHG
106
Westwood Holdings Group
Dallas,
Texas
| – | -$64K | -143 | Closed |
|
107
Acadian Asset Management
Boston,
Massachusetts
| – | -$43K | -97 | Closed |
|
|
PCM
108
Prelude Capital Management
New York
| – | -$21K | -46 | Closed |
|
|
TRCT
109
Tower Research Capital (TRC)
New York
| – | +$638 | +2 | New |
|
EIGR Hedge Fund Activity: Q1 2020 in Review
93 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q1 2020, worth a combined $122M — down 56% from $275M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new EIGR positions and 16 closed out — a net gain of 3 holders — while 41 added to existing stakes and 20 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $19M. The largest seller was Adage Capital Partners, cutting an estimated $21.6M.
- 93 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q1 2020, up from 91 in Q4 2019.
- Funds reported $122M of Eiger BioPharmaceuticals, Inc. stock for Q1 2020, down 56% quarter-over-quarter.
- 19 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q1 2020 and 16 closed out, a net change of +3 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q1 2020 was Vivo Capital, an estimated $19M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q1 2020 was Adage Capital Partners, an estimated $21.6M sold.
Based on aggregated 13F filings for Q1 2020.